Malaria Journal, 2022 Background The enantiomers of the 8-aminoquinoline anti-malarial primaquine have different pharmacological properties. Development of an analytical method for simultaneous quantification of the enantiomers of primaquine and its metabolite ...
Warunee Hanpithakpong +3 more
doaj +1 more source
Malaria Journal, 2021 Background The relapsing nature of Plasmodium vivax infection is a major barrier to its control and elimination. Factors such as adequate dosing, adherence, drug quality, and pharmacogenetics can impact the effectiveness of radical cure of P.
Anielle de Pina-Costa +12 more
doaj +1 more source
Using G6PD tests to enable the safe treatment of Plasmodium vivax infections with primaquine on the Thailand-Myanmar border: A cost-effectiveness analysis. [PDF]
PLoS Neglected Tropical Diseases, 2017 BACKGROUND:Primaquine is the only licensed antimalarial for the radical cure of Plasmodium vivax infections. Many countries, however, do not administer primaquine due to fear of hemolysis in those with glucose-6-phosphate dehydrogenase (G6PD) deficiency.
Angela Devine +7 more
doaj +1 more source
5-Phenoxy Primaquine Analogs and the Tetraoxane Hybrid as Antimalarial Agents
Molecules, 2021 The rapid emergence of drug resistance to the current antimalarial agents has led to the urgent need for the discovery of new and effective compounds.
Somruedee Jansongsaeng +4 more
doaj +1 more source
Single dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission in Cambodia: An open-label randomized trial. [PDF]
PLoS ONE, 2017 BACKGROUND:Single low dose primaquine (SLD PQ, 0.25mg/kg) is recommended in combination with artemisinin-based combination therapy (ACT) as a gametocytocide to prevent Plasmodium falciparum transmission in areas threatened by artemisinin resistance.
Jessica T Lin +16 more
doaj +1 more source
Clinical and parasitological response to oral chloroquine and primaquine in uncomplicated human Plasmodium knowlesi infections [PDF]
, 2013 Background: Plasmodium knowlesi is a cause of symptomatic and potentially fatal infections in humans. There are no studies assessing the detailed parasitological response to treatment of knowlesi malaria infections in man and whether antimalarial ...
Cox Singh, Janet +6 more
core +1 more source
Malaria Journal, 2019 Background The activity and haemolytic toxicity associated with primaquine has been linked to its reactive metabolites. The reactive metabolites are thought to be primarily formed through the action of cytochrome P450-mediated pathways.
Pius S. Fasinu +9 more
doaj +1 more source
Combined DNA extraction and antibody elution from filter papers for the assessment of malaria transmission intensity in epidemiological studies. [PDF]
, 2013 BACKGROUND: Informing and evaluating malaria control efforts relies on knowledge of local transmission dynamics. Serological and molecular tools have demonstrated great sensitivity to quantify transmission intensity in low endemic settings where the ...
Baidjoe, Amrish +13 more
core +3 more sources
Primaquine in vivax malaria: an update and review on management issues
Malaria Journal, 2011 Primaquine was officially licensed as an anti-malarial drug by the FDA in 1952. It has remained the only FDA licensed drug capable of clearing the intra-hepatic schizonts and hypnozoites of Plasmodium vivax.
Fernando Deepika +2 more
doaj +1 more source
Transition from endemic behavior to eradication of malaria due to combined drug therapies: an agent-model approach [PDF]
, 2019 We introduce an agent-based model describing a susceptible-infectious-susceptible (SIS) system of humans and mosquitoes to predict malaria epidemiological scenarios in realistic biological conditions.
Lind, Pedro G. +3 more
core +2 more sources